Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

This study (called TORNADO) is testing whether adding an immunotherapy drug called retifanlimab to standard chemotherapy before surgery improves outcomes for people with certain types of soft-tissue sarcoma (cancerous tumours of the muscles, fat, tendons, or other connective tissue). **You may be eligible if...** - You have a grade 2 or grade 3 soft-tissue sarcoma in the arm, leg, torso, or abdomen, confirmed by biopsy and reviewed by a specialist network - Your tumour shows a feature called tertiary lymphoid structures (TLS), which are clusters of immune cells that may predict better response to immunotherapy - Your cancer has not spread to other parts of the body and can be surgically removed - You have at least one tumour that can be biopsied - You have not previously received treatment for this cancer - You are 18 or older and in adequate health (ECOG 0–1) **You may NOT be eligible if...** - Your sarcoma has spread (metastatic) - Your tumour lacks TLS features on testing - You have already received treatment for this sarcoma - You have serious organ problems or active infections Talk to your doctor to see if this trial is right for you.